203 related articles for article (PubMed ID: 32532820)
21. Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.
Luo D; Liu Y; Lin S; Tan L; Du Z; Long M; Zhu Y; Peng X; Zong W; Mackenzie GG; Li H; Ouyang N
Oncol Rep; 2019 Feb; 41(2):1253-1263. PubMed ID: 30535496
[TBL] [Abstract][Full Text] [Related]
22. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
23. Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.
Garcia-Rendueles AR; Rodrigues JS; Garcia-Rendueles ME; Suarez-Fariña M; Perez-Romero S; Barreiro F; Bernabeu I; Rodriguez-Garcia J; Fugazzola L; Sakai T; Liu F; Cameselle-Teijeiro J; Bravo SB; Alvarez CV
Oncogene; 2017 Feb; 36(5):652-666. PubMed ID: 27452523
[TBL] [Abstract][Full Text] [Related]
24. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
25. CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of β-catenin pathway.
Bi W; Huang J; Nie C; Liu B; He G; Han J; Pang R; Ding Z; Xu J; Zhang J
J Exp Clin Cancer Res; 2018 Nov; 37(1):275. PubMed ID: 30424816
[TBL] [Abstract][Full Text] [Related]
26. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
[TBL] [Abstract][Full Text] [Related]
27. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
[TBL] [Abstract][Full Text] [Related]
28. TRIM30 modulates Interleukin-22-regulated papillary thyroid Cancer cell migration and invasion by targeting Sox17 for K48-linked Polyubiquitination.
Li W; Li F; Lei W; Tao Z
Cell Commun Signal; 2019 Dec; 17(1):162. PubMed ID: 31823782
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
Wen D; Liao T; Ma B; Qu N; Shi RL; Lu ZW; Wang YL; Wei WJ; Ji QH
Cancer Med; 2018 Feb; 7(2):285-296. PubMed ID: 29341469
[TBL] [Abstract][Full Text] [Related]
30. Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.
Luckett KA; Cracchiolo JR; Krishnamoorthy GP; Leandro-Garcia LJ; Nagarajah J; Saqcena M; Lester R; Im SY; Zhao Z; Lowe SW; de Stanchina E; Sherman EJ; Ho AL; Leach SD; Knauf JA; Fagin JA
Endocr Relat Cancer; 2021 May; 28(6):391-402. PubMed ID: 33890869
[TBL] [Abstract][Full Text] [Related]
31. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
32. Cadherin 6 is a new RUNX2 target in TGF-β signalling pathway.
Sancisi V; Gandolfi G; Ragazzi M; Nicoli D; Tamagnini I; Piana S; Ciarrocchi A
PLoS One; 2013; 8(9):e75489. PubMed ID: 24069422
[TBL] [Abstract][Full Text] [Related]
33. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
34. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
[TBL] [Abstract][Full Text] [Related]
35. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.
Colombo C; Minna E; Gargiuli C; Muzza M; Dugo M; De Cecco L; Pogliaghi G; Tosi D; Bulfamante G; Greco A; Fugazzola L; Borrello MG
J Exp Clin Cancer Res; 2020 Nov; 39(1):245. PubMed ID: 33198784
[TBL] [Abstract][Full Text] [Related]
36. The Mediator Subunit MED16 Transduces NRF2-Activating Signals into Antioxidant Gene Expression.
Sekine H; Okazaki K; Ota N; Shima H; Katoh Y; Suzuki N; Igarashi K; Ito M; Motohashi H; Yamamoto M
Mol Cell Biol; 2016 Feb; 36(3):407-20. PubMed ID: 26572828
[TBL] [Abstract][Full Text] [Related]
37.
Wen J; Lin B; Lin L; Chen Y; Wang O
Aging (Albany NY); 2020 Aug; 12(16):16437-16456. PubMed ID: 32857728
[TBL] [Abstract][Full Text] [Related]
38. Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1α and microRNA-146a.
Long M; Zhu Y; Chen Z; Lin S; Peng X; Luo D; Li H; Tan L
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32303750
[TBL] [Abstract][Full Text] [Related]
39. Curcumin enhances the membrane trafficking of the sodium iodide symporter and augments radioiodine uptake in dedifferentiated thyroid cancer cells
Zhang L; Xu S; Cheng X; Wu J; Wang X; Wu L; Yu H; Bao J
Food Funct; 2021 Sep; 12(18):8260-8273. PubMed ID: 34323243
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-31 inhibits papillary thyroid carcinoma cell biological progression by directly targeting SOX11 and regulating epithelial-to-mesenchymal transition, ERK and Akt signaling pathways.
Wang Y; Liu BG; Zhou CX
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5863-5873. PubMed ID: 31298337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
